Roche, Pfizer Race To Find Next Ozempic As Pharma Giants Hustle To Join Obesity Treatment Market
Portfolio Pulse from Neil Dennis
Pharmaceutical companies are racing to develop obesity treatments, with Novo Nordisk and Eli Lilly seeing significant share price increases due to their obesity drugs. Pfizer's development setback has led to a share price decline, while Altimmune's successful drug tests boosted its shares. Roche acquired Carmot Therapeutics to enter the obesity drug market. The Tema Cardiovascular and Metabolics ETF (HRTS) was launched to track the performance of weight loss drugs and their producers.
December 04, 2023 | 9:20 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Pfizer's stock is down 41% this year after halting development of a twice daily version of its weight loss pill, though it plans to bring a once-a-day pill to market next year.
Pfizer's stock decline is a direct result of the halted development of its obesity treatment, indicating a negative short-term impact on the stock.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 80
POSITIVE IMPACT
Altimmune's shares jumped 48% in two days following the announcement of successful tests of its weight-loss drug.
The sharp increase in Altimmune's share price is directly related to the positive results from its weight-loss drug tests, suggesting a strong short-term impact on the stock.
CONFIDENCE 85
IMPORTANCE 85
RELEVANCE 90
POSITIVE IMPACT
The Tema Cardiovascular and Metabolics ETF (HRTS) was launched to track the performance of weight loss drugs and their producers, and is up nearly 3% since its launch two weeks ago.
The HRTS ETF's increase since its launch indicates a positive reception and potential growth in the obesity treatment market, which could positively impact the ETF in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 70
POSITIVE IMPACT
Eli Lilly's share price is up nearly 90% since the launch of its obesity drug Mounjaro in May 2022.
Eli Lilly's stock price increase is closely linked to the successful launch of its obesity drug, suggesting a positive short-term impact on the stock.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 90
POSITIVE IMPACT
Novo Nordisk's share price has jumped around 300% since the launch of its obesity drugs Ozempic and Wegovy in 2019.
The significant share price increase for Novo Nordisk is directly attributed to the success of its obesity drugs, indicating a positive short-term impact on the stock.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 90